Myriad Hits Competitors With Patent Suit, Keeping DNA Patent Debate Alive

Myriad Genetics has filed suit against Ambry Genetics and Gene by Gene, two of its competitors that began marketing less-expensive versions of its diagnostic breast cancer test the same day a unanimous Supreme Court ruled against patenting isolated human DNA.
Drug Industry Daily